TABLE 3.

Summary of IOP, Reduction in IOP From Baseline and Number of IOP-lowering Medications for Each Study Visit

	No. Participants Analyzed		IOP (mm Hg)		No. IOP-lowering Medications		IOP Reduction From Baseline (mm Hg) [P]
Visit	SGDD	CPC	SGDD	CPC	SGDD	CPC	SGDD	CPC
Baseline	22	20	27.6 (±8.7)	26.2 (±9.7)	3.0 (±1.0)	3.3 (±1.1)	—	—
			[15–46]	[13–55]	[0–4]	[1–5]
Week 1	22	19	17.7 (±10.2)	12.7 (±7.3)	1.7* (±1.6)	2.8* (±1.5)	9.9 (±14.4)	13.7 (±7.4)
			[3–46]	[5–40]	[0–4]	[0–4]	[−23.5 to 39]	[−1.5 to 28.5]
							[0.004]	[<0.001]
Month 1	22	18	17.4 (±9.0)	13.2 (±6.2)	1.6 (±1.4)	2.2 (±1.3)	10.1 (±11.7)	12.9 (±9.8)
			[5–36]	[3–27.5]	[0–4]	[0–4]	[−14.5 to 30.5]	[−5 to 31]
							[0.001]	[<0.001]
Month 3	21	18	15.4 (±6.6)	16.0 (±7.5)	1.4 (±1.4)	2.1 (±1.4)	11.5 (±9.3)	10.1 (±7.1)
			[3–31]	[9–42]	[0–4]	[0–4]	[−1.5 to 31]	[−4.5 to 25]
							[<0.001]	[<0.001]
Month 6	19	19	13.5 (±4.2)	13.6 (±4.0)	1.9 (±1.3)	2.2 (±1.2)	13.7 (±9.1)	12.8 (±10.7)
			[4–20]	[5–21]	[0–4]	[0–4]	[2.5–34.5]	[−4.5 to 34]
							[<0.001]	[<0.001]
Month 12	16	16	14.9 (±4.5)	13.9 (±6.3)	2.1 (±1.3)	1.7 (±1.4)	11.6 (±7.6)	12.3 (±7.9)
			[8–24]	[8.5–34.5]	[0–4]	[0–4]	[−3 to 25]	[−5 to 27.5]
							[<0.001]	[<0.001]
Year 2	6	9	14.8 (±6.5)	14.3 (±4.7)	1.5 (±1.6)	1.4 (±1.0)	16.0 (±6.3)	13.11 (±10.6)
			[6.3–25]	[9–24.5]	[0–3]	[0–3]	[7–24]	[3.5–30.5]
							[0.002]	[0.006]
Year 3	6	5	14.6 (±4.4)	12.8 (±3.0)	2.2 (±1.7)	2.2 (±0.8)	18.5 (±8.1)	14.50 (±8.8)
			[9.5–22]	[10–16]	[0–4]	[1–3]	[5–28]	[7–28.5]
							[0.003]	[0.02]

^*For P<0.05.

^**For P<0.01.

^***For P<0.001 Obtained from 2-sample t test or Fisher Exact test for comparing between groups.

All data are presented as mean (±SD) [range].

P-value obtained from paired t test for within each group.

CPC indicates cyclophotocoagulation; IOP, intraocular pressure; SGDD, second glaucoma drainage device.